Saidal Launches DAPAFLUX, New Type 2 Diabetes Treatment
Algerian public pharmaceutical group Saidal has launched DAPAFLUX, an innovative new treatment designed to regulate Type 2 Diabetes and protect against complications, unveiled on November 20, 2026, in Algiers.

The Algerian public pharmaceutical group Saidal officially launched DAPAFLUX, an innovative new treatment for Type 2 Diabetes, in Algiers on Friday, November 20, 2026. This new medication aims to regulate Type 2 Diabetes while also protecting patients from its significant complications.
DAPAFLUX is distinguished by its dual purpose: effective disease control and active prevention of cardiovascular and renal complications, which are major risks for diabetic individuals. The launch was marked by a scientific conference titled “Convergence: a shared approach,” underscoring the collaboration between the pharmaceutical industry and the medical community. The event saw the attendance of Younes Bouarara, Director General of the Saidal group; Abdelhakim Boualdiss, Secretary General of the Ministry of Pharmaceutical Industry, representing Minister Dr. Ouacim Kouidri; Cherif Delih, Director General of the National Agency for Pharmaceutical Products (ANPP); and Professor Amar Tebaibia, president of the multidisciplinary expert committee for the national essential medicines list, alongside various professors, specialist doctors, and Saidal executives.
Younes Bouarara expressed satisfaction, viewing DAPAFLUX's market introduction as a crucial milestone for Saidal. He emphasized that this launch represents a comprehensive strategy to diversify the group's therapeutic areas and consolidate its industrial and technological capabilities. Saidal also reaffirms its fundamental social mission to ensure Algerian citizens have continuous access to high-quality treatments at affordable prices, addressing a key economic and social imperative for chronic diseases requiring long-term care.
This medical and industrial initiative aligns directly with national directives at the highest levels of the state. Abdelhakim Boualdiss highlighted that the development of such innovative treatments fully supports President Abdelmadjid Tebboune's strategic vision. This vision aims to build robust and sustainable health sovereignty, reduce dependence on imports, and significantly enhance the management of chronic diseases across Algeria.




